Theme 2: Identify cellular/molecular determinants and clinically relevant biomarkers of treatment response on which to base therapy

Scientific Accomplishments 

Drs. Bepler, Gadgeel, A Schwartz, and Cote, working with Dr. Bollig-Fischer, identified “driver” mutations in non-small cell lung cancer (NSCLC) in African American and European American patients using the Sequenom MassArray system and a multiplexed panel for 214 oncogenic mutations in 26 genes previously identified in NSCLC. African Americans with NSCLC exhibited multiple genetic mutations more frequently than European Americans with a different mutation profile. These results provided impetus for CAP/CLIA certification of the Genomics Core in 2013 for use of custom panels for lung cancer oncogenes and amplifications/deletions.

  • Lead researchers - Drs. Bepler, Gadgeel, and Bollig-Fischer
  • Collaborative researchers - Drs. Schwartz and Cote

Dr. Ratnam, working with Drs. Gadgeel, Shields, Matherly, and Bepler, demonstrated the role of glucocorticoid receptor (GR) status as a determinant of the variability in the sensitivity of non-small cell lung cancer (NSCLC) cells to pemetrexed (PEM), a S-phase-targeted drug in front-line or maintenance therapy  of advanced NSCLC, generally administered with dexamethasone (Dex). Their results predict that in non-squamous NSCLC, S-phase suppression by Dex, combined with a reduction in PEM transport, attenuates responsiveness to PEM and that GR status is an important determinant of tumor variability of this response.  Based on these in vitro results, an investigator-initiated clinical trial (Shields, Lead PI; Ratnam, Gadgeel, Heilbrun, collaborators) is enrolling NSCLC patients who will be screened by RT-PCR for high levels of GRα, then imaged with FLT-PET to test the hypothesis that Dex will decrease S-phase progression, as reflected in decreased activity of thymidine kinase-1.

  • Lead researchers - Drs. Ratnam. Gadgeel, Shields, Matherly and Bepler.
  • Collaborative researcher - Dr. Heilbrun

The Latest From Karmanos Cancer Institute

News

U CAN-CER VIVE Gives $450K+ to Karmanos Cancer Institute for Continued Research in Using Radiofrequency to Treat Cancer

The Barbara Ann Karmanos Cancer Institute has been awarded $459,010 for continued research in treating cancers with radiofrequency electromagnetic...

Read More

New Grant Allows Karmanos Researchers to Continue Research Using Electromagnetic Radiofrequency Fields to Treat Fibrolamellar Carcinoma

A Barbara Ann Karmanos Cancer Institute and Wayne State University research team has received a $49,500 grant to research a rare cancer. The grant...

Read More

IN THE NEWS – New Hope for Myeloma Patients: Karmanos Advances Treatment and Survival

Telegram News Craig Cole, M.D. , malignant hematologist and member of the  Hematology Oncology  and  Multiple Myeloma and Amyloidos...

Read More
News

WDET | Doctor Says HPV Vaccine and Routine Screenings Aid Against Cervical Cancer

Listen Now

WWJ | World Cancer Day

Listen Now

WWJ | Ribbon Cutting Held for New Karmanos Cancer Center in Dearborn That Strives to Improve Access to Treatment, Clinical Trials

Listen Now